1. Home
  2. KALA vs WVVI Comparison

KALA vs WVVI Comparison

Compare KALA & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • WVVI
  • Stock Information
  • Founded
  • KALA 2009
  • WVVI 1983
  • Country
  • KALA United States
  • WVVI United States
  • Employees
  • KALA N/A
  • WVVI N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • WVVI Beverages (Production/Distribution)
  • Sector
  • KALA Health Care
  • WVVI Consumer Staples
  • Exchange
  • KALA Nasdaq
  • WVVI Nasdaq
  • Market Cap
  • KALA 26.2M
  • WVVI 28.2M
  • IPO Year
  • KALA 2017
  • WVVI N/A
  • Fundamental
  • Price
  • KALA $5.97
  • WVVI $4.81
  • Analyst Decision
  • KALA Strong Buy
  • WVVI
  • Analyst Count
  • KALA 3
  • WVVI 0
  • Target Price
  • KALA $14.00
  • WVVI N/A
  • AVG Volume (30 Days)
  • KALA 135.3K
  • WVVI 26.5K
  • Earning Date
  • KALA 08-05-2025
  • WVVI 08-12-2025
  • Dividend Yield
  • KALA N/A
  • WVVI N/A
  • EPS Growth
  • KALA N/A
  • WVVI N/A
  • EPS
  • KALA N/A
  • WVVI N/A
  • Revenue
  • KALA N/A
  • WVVI $38,520,945.00
  • Revenue This Year
  • KALA N/A
  • WVVI N/A
  • Revenue Next Year
  • KALA N/A
  • WVVI N/A
  • P/E Ratio
  • KALA N/A
  • WVVI N/A
  • Revenue Growth
  • KALA N/A
  • WVVI N/A
  • 52 Week Low
  • KALA $2.92
  • WVVI $3.17
  • 52 Week High
  • KALA $11.20
  • WVVI $7.18
  • Technical
  • Relative Strength Index (RSI)
  • KALA 60.41
  • WVVI 30.03
  • Support Level
  • KALA $5.39
  • WVVI $5.21
  • Resistance Level
  • KALA $6.30
  • WVVI $5.75
  • Average True Range (ATR)
  • KALA 0.70
  • WVVI 0.28
  • MACD
  • KALA 0.05
  • WVVI -0.05
  • Stochastic Oscillator
  • KALA 60.98
  • WVVI 10.00

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About WVVI Willamette Valley Vineyards Inc.

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

Share on Social Networks: